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tDITORIAL COMMENT
ow and Lowered
holesterol and Total Mortality*
ichael H. Criqui, MD, MPH,†‡
eatrice A. Golomb, MD, PHD†§
an Diego, California
he paper by Strandberg et al. (1) in this issue of the Journal
onfirms that in relatively young, healthy men from higher
ocioeconomic strata, a (naturally) low total cholesterol
TC) is associated with increased longevity (2); on average,
uch men will have lower levels of low-density lipoprotein
LDL) cholesterol. Thus, if you are fortunate to have a low
C as a young man, typically a product of a lot of nature and
little nurture, you can expect to do a little better than your
eers not so favored.
Can one extrapolate these mortality benefits of naturally
ow TC in advantaged middle-aged men to middle-aged
en of lower socioeconomic status (SES)? Can they be
xtrapolated to the very low end of the lipid range, or to TC
owered by treatment, or to women or to elderly persons? In
ach case, the available evidence suggests perhaps not.
See page 1002
owest levels. Several prospective population studies have
uggested that the mortality benefit associated with lower
C plateaus at levels around 180 mg/dl (3). Indeed, total
ortality actually appears to increase somewhat at levels
elow 180 mg/dl, a finding partially but not completely
xplained by illness-related reductions in TC and confound-
ng (3). This study does not contradict those observations.
he cohort of Finnish men in this study had generally high
holesterols by current standards; only 8% of the population
ad a TC 194 mg/dl (5.0 mmol/l), and when the authors
plit this group in half, the lower half, with TCs 182
g/dl (4.7 mmol/l), actually had a slightly higher mortality
27.2%) than the upper half (24.5%). Although the numbers
ere small and this difference was not significant, the result
s concordant with a summary analysis of population studies
f both men and women (3).
owered by treatment. Lowered TC, either by behavioral
ntervention or—much more potently—by drug therapy, is
question distinct from naturally low TC. The evidence
hat pharmacologic therapy of dyslipidemia in higher risk
iddle-aged men results in a total mortality benefit is
xtensive and convincing (4). However, from the limited
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarly represent the views of JACC or the
merican College of Cardiology.
From the UCSD School of Medicine, †Division of Epidemiology, Department of
amily and Preventive Medicine, ‡Division of Cardiology, §Division of General
mnternal Medicine, Department of Medicine, San Diego, California.linical trial evidence available, lowering TC or LDL
holesterol alone produces no independent benefit for clin-
cal events after the ratio of TC to high-density lipoprotein
HDL) cholesterol has been considered (5,6). In only two
linical trials has the issue of the most relevant lipid measure
hange been addressed, and change in either the TC/HDL
atio (5) or the apolipoprotein (apo) B/apoA1 ratio (6)
ccounted for all the benefit from drug therapy. After
onsideration of changes in these ratios, changes in TC and
DL added no predictive value. Conversely, changes in
hese ratios remained strong predictors even after consider-
tion of changes in TC and LDL. The benefits of statins
nd other dyslipidemic drugs appear proportional to the
egree of improvement in the TC/HDL ratio, and by far
he largest reductions in event rates reported to date
ccurred with combination statin and niacin therapy, with
he attendant profound lowering of the TC/HDL ratio (7).
merging data on the dramatic HDL-increasing effects of
holesterol ester transfer protein inhibitors may prove im-
ortant for future therapy (8).
Increasingly, evidence shows that the level of TC or LDL
lone is a poor guide to whether to begin therapy. A recent
rial of high-risk patients showed proportional benefit at
very level of baseline TC and LDL (9), making use of such
riteria for guiding therapy in high-risk patients (as con-
rasted with assessing risk) of questionable value.
omen. What about extrapolations to women? To date,
here is no evidence for a total mortality benefit in women
rom dyslipidemia therapy. Two of three trials that have
eleased data on gender-specific total mortality with lipid
herapy (6,10) have actually shown increases in the treat-
ent group of 57% and 12%, respectively, whereas the third
eported a 1% decrease (11). None of these differences was
ndividually statistically significant. The authors of this
ditorial have not been successful in obtaining gender-
pecific mortality data from other trials to further evaluate
his question, even from trials completed more than a
ecade ago. The Cholesterol Treatment Trialists Collabo-
ation is reportedly addressing such questions. However, a
ubMed search revealed only two publications to date from
his group: both were methods papers, and both were nearly
decade old (12,13). We believe these questions have some
rgency. (Since the initial submission of this editorial, a
eta-analysis of drug treatment of hyperlipidemia in women
as come to a similar conclusion, and the authors have expressed
similar frustration at their inability to obtain gender-specific
ata from many studies [14]).
ES. What of socioeconomic status? In this study all were
men from the highest social class,” a fact that is extenuated
y noting, “in the present study we examined within-group
ifferences, which are probably less sensitive to the selective
ature of the cohort.” However, a meta-analysis by Law and
hompson (15) showed that the relation of low cholesterol
o cancer on long-term follow-up was not evident in a
eta-analysis of high-SES samples but was evident and
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Editorial Comment September 1, 2004:1009–10ignificant in meta-analyses of populations of low SES.
ndeed, there appeared to be a graded relationship from
igh-SES populations, to mixed SES, to low SES. This
nding cannot be glibly dismissed because there are plau-
ible effect modifiers linked to SES, such as dietary and
nvironmental differences.
lderly. Can we extrapolate the favorable observations
oncerning low TC in younger persons to older persons?
he best evidence is—not really. This article does not
ddress the prognostic implications of low TC once old age
s attained. Some evidence suggests that elevated TC in old
ge is protective (16), and other evidence indicates that in
he same person, a TC measured at an older age is much less
redictive than a TC measured at a younger age, and a TC
easured more distant in time is more predictive than a
ecent one, even after adjusting each TC measure for the
ther (17). Only consideration of HDL cholesterol allows
uch predictive power at middle or older ages (18).
Finally, if TC is a poor predictor in the elderly, or perhaps
ven a protective factor, should we lower TC in elderly
ersons? Certainly they are at high cardiovascular risk and,
rom this standpoint, should benefit from intervention if
omparable relative risk reductions obtain and benefits are
ot undercut by unsuspected hazards. To date only one
rial—Prospective Study of Pravastatin in the Elderly at
isk (PROSPER)—has specifically randomized a large
umber of elderly patients (age 70 to 82 years, mean 75
ears) to drug therapy, and all were also at elevated vascular
isk for reasons in addition to age (19). The results were not
eassuring. The overall benefit for vascular events was a
odest 15%, there was no benefit for vascular events in
omen, there was no benefit for stroke, and there was no
enefit for total mortality in both genders combined (readers
ere not provided gender-specific mortality rates). Moreover,
here was a disturbing significant excess of incident cancer in
he treatment group, reminding us that elderly persons are at
ncreased risk for cancer as well as cardiovascular disease.
In conclusion, low TC is not uniformly a good thing, and
any unanswered questions remain. Appropriate access to
elevant data would help clarify some of these questions for
esearchers and clinicians alike. There is a natural tendency
y authors to highlight the most positive findings in their
tudy, particularly where commercial sponsorship is in-
olved. Perhaps medical journals, as a prerequisite for
ublication, should require investigators and sponsors to
ake study data accessible after a suitable period to pre-
lude, or at least attenuate, bias in publication.
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